Anti-synthetase syndrome: 2026 so far

More ILD treatment experiments appeared, alongside clearer safety trade-offs.

In January 2026 to September 2026, several early (non-randomized) treatment reports added possible signals for ASyS-ILD. Telitacicept given with glucocorticoids (steroid medicines that reduce inflammation) was followed by improved lung function and walking distance over 24 weeks in a small mixed autoimmune-ILD group that included ASyS. A very small series of refractory (hard-to-treat) ASyS-ILD reported symptom relief and DLCO (a breathing test that reflects gas transfer in the lungs) improvement after combining tofacitinib with tacrolimus, along with steroid reduction. A systematic review/meta-analysis also summarized that calcineurin inhibitors (tacrolimus or cyclosporine) plus steroids often lined up with stable or improved ILD, while also reporting that relapses were common even on treatment. In these reports, infections came up repeatedly with intensive or combination approaches (e.g., respiratory infections with blinatumomab; infections including shingles and deaths during follow-up in the tofacitinib+tacrolimus series), which means any possible lung benefit signals need to be weighed against safety uncertainty for someone living with ILD.

Research covered in: February 2026, April 2026, September 2026

Real-world data linked 6-month steroid dose to infection and flare patterns.

One retrospective (looking back at records) ASyS-ILD cohort suggested that steroid exposure over time moved with different risks. Reaching a lower prednisolone-equivalent dose by 6 months (<=15 mg/day) was linked with fewer infections requiring hospitalization. In the same dataset, a mid-range 6-month dose group (12.5-15 mg/day) tended to have the lowest flare (worsening of disease) risk. This points to a possible trade-off between infection risk and relapse risk in routine care. Because patients were not randomized to different tapering targets, these results show associations rather than proving that a specific taper caused better outcomes, but they help clarify which risks tended to rise or fall together in that cohort while managing ILD and steroid side effects.

Research covered in: May 2026

Studies increasingly separated ILD into distinct trajectories and risk groups.

In the January 2026 to September 2026 reports, lung monitoring moved from describing broad variability to proposing specific ways to sort ILD into different courses over time. CT (computed tomography, a detailed X-ray scan) patterns were repeatedly linked to different lung-function paths. One cohort identified three FVC (forced vital capacity, how much air you can blow out) trajectory groups, where CT pattern was the strongest predictor of worsening versus stable/improving courses. Several studies also emphasized that the amount of lung affected may matter. CT scores and automated CT measures tracked strongly with breathing tests in one follow-up cohort. A separate myositis-ILD cohort reported that CT-measured fibrosis/overall ILD burden (and 12-month worsening) predicted mortality, while visual CT reading alone did not. Recurrence after initial improvement was also reported (24 of 76 in one study), with pyrexia of unknown origin (fever without a clear cause) linked to higher recurrence risk and NSIP-only pattern (a specific ILD pattern called nonspecific interstitial pneumonia) linked to lower risk, reinforcing that ILD can change direction and may need ongoing tracking over time.

Research covered in: January 2026, April 2026, June 2026, July 2026

Ro52 and lung markers recurred; pulmonary hypertension emerged as a major outcome signal.

Several reports connected anti-Ro52 (an autoantibody, meaning an immune protein that targets the body) with lung-related risk, but the meaning was not the same in every dataset. One ASyS-ILD cohort found anti-Ro52 positivity associated with higher incidence of ILD recurrence or ILD-related death. Another large cohort found anti-Ro52 was common and linked to pulmonary involvement but did not clearly separate prognosis within ASyS. Blood markers were also explored. KL-6 (a blood marker linked with lung injury) was higher in inflammatory myopathy patients with ILD, and higher baseline KL-6 lined up with later hospitalization and radiologic worsening in one small prospective (following people forward over time) cohort. In a smaller longitudinal study (in those with isolated organ involvement), falling anti-ARS (anti-aminoacyl tRNA synthetase) antibody levels tracked with improvement in KL-6. A major complication signal came from a large international registry: pulmonary hypertension (high blood pressure in the lung arteries) was reported in 8.9% of ASyS and was linked to worse survival even after accounting for age, sex, and ILD, making it an outcome clinicians may need to recognize and evaluate in the months covered.

Research covered in: May 2026, June 2026, August 2026, September 2026

Multiple studies showed weak positives often fail confirmation; new interpretation tools emerged.

So far in 2026, several studies pointed to the same practical issue: antisynthetase antibody results are most useful when read in clinical context and often need confirmation, especially when the initial signal is weak. Real-world data showed myositis antibody panels matched true inflammatory muscle disease more often when ordered for suspected myositis. Several studies also found that some initial antisynthetase antibody positives were not confirmed on follow-up or central testing. This included a multi-lab study where only 27% of line-blot positives were confirmed, and very low/low intensities were rarely confirmed. Newer or refined approaches were proposed to reduce uncertainty. These included a LIPS method (luciferase immunoprecipitation system, a lab test for detecting antibodies) that agreed closely with a reference method and outperformed line blot in one study, and a diagnostic score combining line-blot intensity with cytoplasmic staining pattern and anti-Ro52 to separate low/intermediate/high probability zones. This means the same antibody label can carry different levels of certainty depending on why testing was done, how strong the signal was, and whether confirmatory methods were used.

Research covered in: January 2026, February 2026, March 2026, May 2026, June 2026